Cancer systems biology

Methods in Molecular Biology

Volumn 662, Issue , 2010, Pages 245-263

  Faratian, Dana ^a   Bown, James L ^a   Smith, V Anne ^b   Langdon, Simon P ^c   Harrison, David J ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ABERTAY DUNDEE   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Bayesian networks; Cancer; Oncology; S systems; Systems biology; Targeted therapeutics

Indexed keywords

EID: 84934440840     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-800-3_12     Document Type: Article

References (64)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
2. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113
3. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527
4. Sobin LH, Wittekind CH (2002) UICC: TNM classification of malignant tumors. Wiley-Liss, New York
5. Faratian D, Bartlett J (2008) Predictive markers in breast cancer - the future. Histopathology 52:91-98
6. Payne SJ, Bowen RL, Jones JL, Wells CA (2008) Predictive markers in breast cancer - the present. Histopathology 52:82-90
7. Faratian D, Moodie SL, Harrison DJ, Goryanin I (2007) Dynamic computational modeling in the search for better breast cancer drug therapy. Pharmacogenomics 8:1757-1761
8. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508
9. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715
10. Kholodenko BN (2006) Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol 7:165-176
11. Faratian D, Goltsov A, Lebedeva G, Sorokin A, Mullen P, Kay C, Um I, Langdon SP, Goryanin I, Harrison DJ (2009) Systems biology reveals new strategies for personalising cancer medicine and confirms PTEN''s role in resistance to trastuzumab. Cancer Res 69:6713-6720
12. Piccart-Gebhart MJ, Procter M, Leyland- Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
13. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
14. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402
15. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127
16. Fuss H, Dubitzky W, Downes CS, Kurth MJ (2005) Mathematical models of cell cycle regulation. Brief Bioinform 6:163-177
17. Hatakeyama M, Kimura S, Naka T, Kawasaki T, Yumoto N, Ichikawa M, Kim JH, Saito K, Saeki M, Shirouzu M, Yokoyama S, Konagaya A (2003) A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin- induced ErbB signalling. Biochem J 373:451-463
18. Hendriks BS, Cook J, Burke JM, Beusmans JM, Lauffenburger DA, de Graaf D (2006) Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase activity. Syst Biol (Stevenage) 153: 22-33
19. Kholodenko BN, Demin OV, Moehren G, Hoek JB (1999) Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem 274:30169-30181
20. Markevich NI, Hoek JB, Kholodenko BN (2004) Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades. J Cell Biol 164: 353-359
21. Shankaran H, Wiley HS, Resat H (2006) Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. Biophys J 90:3993-4009
22. Steuer R (2007) Computational approaches to the topology, stability and dynamics of metabolic networks. Phytochemistry 68: 2139-2151
23. Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, Kholodenko BN (2007) Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. Mol Syst Biol 3:144
24. Moehren G, Markevich N, Demin O, Kiyatkin A, Goryanin I, Hoek JB, Kholodenko BN (2002) Temperature dependence of the epidermal growth factor receptor signaling network can be accounted for by a kinetic model. Biochemistry 41:306-320
25. Schoeberl B, Eichler-Jonsson C, Gilles ED, Muller G (2002) Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol 20:370-375
26. Clyde RG, Craig AL, de Breed L, Bown JL, Forrester L, Vojtesek B, Smith G, Hupp T, Crawford J (2009) A novel ataxia-telangiectasia mutated autoregulatory feedback mechanism in murine embryonic stem cells. J R Soc Interface 6:1167-1177
27. Gueven N, Fukao T, Luff J, Paterson C, Kay G, Kondo N, Lavin MF (2006) Regulation of the Atm promoter in vivo. Genes Chromosomes Cancer 45:61-71
28. Heckerman D, Geiger D, Chickering D (1995) Learning Bayesian networks: the combination of knowledge and statistical data. Mach Learn 20:197-243
29. Pearl J (1988) Probabilistic reasoning in intelligent systems. Morgan Kaufmann, San Francisco
30. Friedman N (2004) Inferring cellular networks using probabilistic graphical models. Science 303:799-805
31. Kim SY, Imoto S, Miyano S (2003) Inferring gene networks from time series microarray data using dynamic Bayesian networks. Brief Bioinform 4:228-235
32. Imoto S, Kim S, Goto T, Miyano S, Aburatani S, Tashiro K, Kuhara S (2003) Bayesian network and nonparametric heteroscedastic regression for nonlinear modeling of genetic network. J Bioinform Comput Biol 1:231-252
33. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP (2005) Causal protein-signaling networks derived from multiparameter single-cell data. Science 308:523-529
34. Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, Harsha HC, Sato M, Bader JS, Lash AE, Minna JD, Pandey A, Varmus HE (2008) Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA 105:14112-14117
35. Li Z, Chan C (2004) Inferring pathways and networks with a Bayesian framework. FASEB J 18:746-748
36. Gevaert O, De Smet F, Timmerman D, Moreau Y, De Moor B (2006) Predicting the prognosis of breast cancer by integrating clinical and microarray data with Bayesian networks. Bioinformatics 22:e184-e190
37. Matthäus F, Smith VA, Fogtman A, Sommer WH, Leonardi-Essmann F, Lourdusamy A, Reimers MA, Spanagel R, Gebicke-Haerter PJ (2009) Interactive molecular networks obtained by computer-aided conversion of microarray data from brains of alcohol-drinking rats. Pharmacopsychiatry 42:S118-S128
38. Sorribas A, Savageau MA (1989) A comparison of variant theories of intact biochemical systems. I. Enzyme-enzyme interactions and biochemical systems theory. Math Biosci 94:161-193
39. Savageau MA, Voit EO (2008) Power-law approach to modeling biological systems. 1. Theory, 60th edn. pp 519-544
40. Voit EO (2002) Models-of-data and modelsof- processes in the post-genomic era. Math Biosci 180:263-274
41. Kitano H (2004) Biological robustness. Nat Rev Genet 5:826-837
42. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA Jr, Marks JR, Dressman HK, West M, Nevins JR (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357
43. Wulfkuhle J, Espina V, Liotta L, Petricoin E (2004) Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer 40: 2623-2632
44. Moodie SL, Sorokin A, Goryanin I, Ghazal P (2009) Graphical notation to describe the logical interactions of biological pathways. J Integr Bioinform 3:36
45. Calzone L, Gelay A, Zinovyev A, Radvanyi F, Barillot E (2008) A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Syst Biol 4:173
46. Le Novere N, Moodie SL, Sorokin A, Hucka M, Schreiber F, Demir E, Mi H, Matsuoka Y, Wegner K, Kitano H (2008) Systems biology graphical notation: process diagram level 1. Nature Precedings
47. Saltelli A, Ratto M, Andres T, Campolongo F, Cariboni J, Gatelli D, Saisana M, Tarantola S (2008) Global sensitivity analysis: the primer. Wiley, Chichester
48. Pachepsky E, Crawford JW, Bown JL, Squire G (2001) Towards a general theory of biodiversity. Nature 410:923-926
49. Saltelli A, Tarantola S, Chan K (1999) Quantatative model-independent method for sensitivity analysis of model output. Technometrics 41:39-56
50. Feng XJ, Hooshangi S, Chen D, Li G, Weiss R, Rabitz H (2004) Optimizing genetic circuits by global sensitivity analysis. Biophys J 87:2195-2202
51. Goldberg D (1989) Genetic algorithms in search, optimization, and machine learning. Addison-Wesley, Reading, MA
52. Kirby J, Heath PR, Shaw PJ, Hamdy FC (2007) Gene expression assays. Adv Clin Chem 44:247-292
53. Kennett JY, Watson SK, Saprunoff H, Heryet C, Lam WL (2008) Technical demonstration of whole genome array comparative genomic hybridization. J Vis Exp, 870
54. Edwards RA (2007) Laser capture microdissection of mammalian tissue. J Vis Exp, 309
55. Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8:1323-1327
56. Pan S, Aebersold R, Chen R, Rush J, Goodlett DR, McIntosh MW, Zhang J, Brentnall TA (2008) Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 8(2):787-797
57. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM (2006) Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5:2512-2521
58. Kedrin D, Gligorijevic B, Wyckoff J, Verkhusha VV, Condeelis J, Segall JE, van Rheenen J (2008) Intravital imaging of metastatic behavior through a mammary imaging window. Nat Methods 5:1019-1021
59. Edward M (2001) Melanoma cell-derived factors stimulate glycosaminoglycan synthesis by fibroblasts cultured as monolayers and within contracted collagen lattices. Br J Dermatol 144:465-470
60. Dixon JM (2004) The scientific value of preoperative studies and how they can be used. Breast Cancer Res Treat 87(Suppl 1):S19-S26
61. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, A'Hern R (2006) Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res 12:1024s-1030s
62. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167-170
63. Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB (2002) Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol 20:3944-3946
64. Nagtegaal ID, Gaspar CG, Peltenburg LT, Marijnen CA, Kapiteijn E, van de Velde CJ, Fodde R, van Krieken JH (2005) Radiation induces different changes in expression profiles of normal rectal tissue compared with rectal carcinoma. Virchows Arch 446:127-135